Korro Bio (KRRO) Equity Average (2019 - 2025)
Korro Bio (KRRO) has disclosed Equity Average for 6 consecutive years, with $107.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 43.31% year-over-year to $107.1 million, compared with a TTM value of $107.1 million through Sep 2025, down 43.31%, and an annual FY2024 reading of $165.2 million, up 366.04% over the prior year.
- Equity Average was $107.1 million for Q3 2025 at Korro Bio, down from $127.0 million in the prior quarter.
- Across five years, Equity Average topped out at $188.9 million in Q3 2024 and bottomed at -$144.3 million in Q3 2023.
- Average Equity Average over 5 years is $78.5 million, with a median of $107.1 million recorded in 2025.
- The sharpest move saw Equity Average crashed 408.34% in 2023, then skyrocketed 1941.83% in 2024.
- Year by year, Equity Average stood at $52.5 million in 2021, then crashed by 116.26% to -$8.5 million in 2022, then skyrocketed by 197.63% to $8.3 million in 2023, then surged by 1941.83% to $170.0 million in 2024, then plummeted by 37.03% to $107.1 million in 2025.
- Business Quant data shows Equity Average for KRRO at $107.1 million in Q3 2025, $127.0 million in Q2 2025, and $149.7 million in Q1 2025.